BACULOVIRUS-BASED ENTEROVIRUS 71 VLP AS A VACCINE
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Feb 12, 2015
app pub date -
Mar 22, 2013
filing date -
Mar 23, 2012
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
An optimized baculovirus/insect cell-mediated system is provided for the production of enterovirus 71 virus-like particles to produce a vaccine against recent EV71 virus outbreaks. Co-expression of the viral capsid polyprotein P1 ORF derived from a fatal case in the Fuyang province of the People's Republic of China plus the 3 CD protease of EV71 prototype strain BrCr resulted in the formation of VLPs. The yields were increased by co-expression of both P1 and 3CD in separate transgene cassettes arranged in opposite orientation in a bicistronic baculovirus vector and by inserting the translational enhancing signal L21 in front of the capsid protein open reading frame. Faster transgene processing was achieved by using insect Sf21 cells instead of Sf9 cells.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully